Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO Breast 2024 | Sequencing first-line CDK4/6 inhibitors in metastatic breast cancer

Stephanie Graff • 16 May 2024
ESMO Breast 2024
Breast Cancer Abemaciclib Palbociclib Ribociclib
MONARCH 3

Stephanie Graff, MD, FACP, FASCO, Brown University, Providence, RI, comments on the role of CDK4/6 inhibitors such as palbociclib, ribociclib, and abemaciclib for patients with metastatic breast cancer. Whilst ribociclib has been proven to have a statistically significant overall survival advantage, abemaciclib does not in the MONARCH 3 (NCT02246621) when combined with aromatase inhibitors. CDK4/6 inhibitors in general are typically used in the first-line setting based on tolerability and comorbidities and ribociclib is often the inhibitor of choice. This interview took place at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Stephanie Graff

Ask the Expert: Stephanie Graff answers your breast cancer questions at ESMO 2025
9:52
Ask the Expert: Stephanie Graff answers your breast cancer questions at ESMO 2025
Stephanie Graff • 18 Oct 2025
Evaluating patient experiences in a multidisciplinary breast cancer clinic
1:21
Evaluating patient experiences in a multidisciplinary breast cancer clinic
Stephanie Graff • 16 May 2024
NATALEE and monarchE: ribociclib and abemaciclib in HR+/HER2- breast cancer
1:48
NATALEE and monarchE: ribociclib and abemaciclib in HR+/HER2- breast cancer
Stephanie Graff • 16 May 2024
ELAINE 1: ESR1 mutations in ctDNA from ER+/HER2- mBC treated with lasofoxifene or fulvestrant
2:06
ELAINE 1: ESR1 mutations in ctDNA from ER+/HER2- mBC treated with lasofoxifene or fulvestrant
Stephanie Graff • 7 Dec 2022

Related Videos

Stress and depression linked to tumor transcriptional signatures in breast cancer
1:21
Stress and depression linked to tumor transcriptional signatures in breast cancer
Shipra Gandhi • 31 May 2026
DESTINY-Breast07: final analysis of T-DXd and durvalumab in 1L HER2+ breast cancer
1:13
DESTINY-Breast07: final analysis of T-DXd and durvalumab in 1L HER2+ breast cancer
Shipra Gandhi • 31 May 2026
TBCRC-053: preoperative radiotherapy & pembrolizumab in node-positive TNBC
1:34
TBCRC-053: preoperative radiotherapy & pembrolizumab in node-positive TNBC
Shipra Gandhi • 1 Jun 2026
HELEN-Trio 011: camrelizumab plus chemotherapy as neoadjuvant therapy in TNBC
0:49
HELEN-Trio 011: camrelizumab plus chemotherapy as neoadjuvant therapy in TNBC
Shipra Gandhi • 1 Jun 2026
The content of VJOncology is intended for healthcare professionals